Journal article
bioRxiv, 2024
APA
Click to copy
Maddineni, A., Liang, Z., Jambardi, S., Roy, S., Tycko, J., Patil, A., … Gottwein, E. (2024). Cytotoxicity of Activator Expression in CRISPR-based Transcriptional Activation Systems. BioRxiv.
Chicago/Turabian
Click to copy
Maddineni, Aakaanksha, Ziyan Liang, Shreya Jambardi, Subrata Roy, Josh Tycko, Ajinkya Patil, Mark Manzano, and Eva Gottwein. “Cytotoxicity of Activator Expression in CRISPR-Based Transcriptional Activation Systems.” bioRxiv (2024).
MLA
Click to copy
Maddineni, Aakaanksha, et al. “Cytotoxicity of Activator Expression in CRISPR-Based Transcriptional Activation Systems.” BioRxiv, 2024.
BibTeX Click to copy
@article{aakaanksha2024a,
title = {Cytotoxicity of Activator Expression in CRISPR-based Transcriptional Activation Systems},
year = {2024},
journal = {bioRxiv},
author = {Maddineni, Aakaanksha and Liang, Ziyan and Jambardi, Shreya and Roy, Subrata and Tycko, Josh and Patil, Ajinkya and Manzano, Mark and Gottwein, Eva}
}
CRISPR-based transcriptional activation (CRISPRa) has extensive research and clinical potential. Here, we show that commonly used CRISPRa systems can exhibit pronounced cytotoxicity. We demonstrate the toxicity of published and new CRISPRa vectors expressing the activation domains (ADs) of the transcription factors p65 and HSF1, components of the synergistic activation mediator (SAM) CRISPRa system. Based on our findings for the SAM system, we extended our studies to additional ADs and the p300 acetyltransferase core domain. We show that the expression of potent transcriptional activators in lentiviral producer cells leads to low lentiviral titers, while their expression in the transduced target cells leads to cell death. Using inducible lentiviral vectors, we could not identify an activator expression window for effective SAM-based CRISPRa without measurable toxicity. The toxicity of current SAM-based CRISPRa systems hinders their wide adoption in biomedical research and introduces selection bottlenecks that may confound genetic screens. Our results suggest that the further development of CRISPRa technology should consider both the efficiency of gene activation and activator toxicity.